Sr VP, CFO of Theravance Inc. (THRX, Financial) Michael W Aguiar sells 10,000 shares of THRX on 12/03/2010 at an average price of $26.51 a share.
Theravance Inc. has a market cap of $1.96 billion; its shares were traded at around $26.5 with and P/S ratio of 80.4.
THRX is in the portfolios of Seth Klarman of The Baupost Group, Julian Robertson of Tiger Management, John Griffin of Blue Ridge Capital, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
Theravance Inc. has a market cap of $1.96 billion; its shares were traded at around $26.5 with and P/S ratio of 80.4.
THRX is in the portfolios of Seth Klarman of The Baupost Group, Julian Robertson of Tiger Management, John Griffin of Blue Ridge Capital, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
Directors and Officers Recent Trades:
- Buy: 10% Owner Plc Glaxosmithkline bought 5,750,000 shares of THRX stock on 11/29/2010 at the average price of 22.5. Plc Glaxosmithkline owns at least 5,750,000 shares after this. The price of the stock has increased by 17.78% since.
- Sell: Head of Business Dev. David L Brinkley sold 1,980 shares of THRX stock on 09/14/2010 at the average price of 15.12. David L Brinkley owns at least 32,351 shares after this. The price of the stock has increased by 75.26% since.
- Sell: SVP, Research & Early Clin Dev Mathai Mammen sold 4,416 shares of THRX stock on 09/01/2010 at the average price of 12.84. Mathai Mammen owns at least 117,566 shares after this. The price of the stock has increased by 106.39% since.
- Sell: Head of Business Dev. David L Brinkley sold 67,032 shares of THRX stock on 06/15/2010 at the average price of 15.55. David L Brinkley owns at least 35,238 shares after this. The price of the stock has increased by 70.42% since.
